Neurofibromatosis: A Review of NF1, NF2, and Schwannomatosis

Abstract

The neurofibromatoses are a heterogeneous group of hereditary cancer syndromes that lead to tumors of the central and peripheral nervous systems, as well as other organ systems. By far the most common form is neurofibromatosis 1 (96%), followed by neurofibromatosis 2 (3%), and a more recently recognized, lesser known form, schwannomatosis. The diagnostic criteria, pathogenesis, molecular considerations, and clinical manifestations are discussed in this review article.

Keywords

neurofibromatosis - NF1 - von Recklinghausen disease - NF2 - schwannomatosis

• References

• 1 DeBella K, Szudek J, Friedman JM. Use of the national institutes of health criteria for diagnosis of neurofibromatosis 1 in children. Pediatrics 2000; 105 (3 Pt 1) 608-614
• 2 Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol 2014; 13 (8) 834-843
• 3 Weiss S , et al. Enzinger and Weiss's Soft Tissue Tumors. Philadelphia, PA. Elsevier Saunders; 2014
• 4 Brosius S. A history of von Recklinghausen's NF1. J Hist Neurosci 2010; 19 (4) 333-348
• 5 Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis type 1 revisited. Pediatrics 2009; 123 (1) 124-133
• 6 Abramowicz A, Gos M. Neurofibromin in neurofibromatosis type 1 - mutations in NF1gene as a cause of disease. Dev Period Med 2014; 18 (3) 297-306
• 7 Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. J Am Acad Dermatol 2009; 61 (1) 1-14 , quiz 15–16
• 8 Ferner RE. Neurofibromatosis 1. Eur J Hum Genet 2007; 15 (2) 131-138
• 9 Rosai J , et al. Rosai and Ackerman's Surgical Pathology. 10th ed. Philadelphia, PA: Elsevier Saunders; 2011
• 10 Robertson KA, Nalepa G, Yang FC , et al. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol 2012; 13 (12) 1218-1224
• 11 Crowe FW , et al. A Clinical, Pathological and Genetic Study of Multiple Neurofibromatosis. Springfield, IL: Charles C Thomas; 1956
• 12 Alper J, Holmes LB, Mihm Jr MC. Birthmarks with serious medical significance: nevocullular nevi, sebaceous nevi, and multiple café au lait spots. J Pediatr 1979; 95 (5 Pt 1): 696-700
• 13 Shimbashi T, Kamide R, Hashimoto T. Long-term follow-up in treatment of solar lentigo and café-au-lait macules with Q-switched ruby laser. Aesthetic Plast Surg 1997; 21 (6) 445-448
• 14 Yanoff M, Sassani J. Ocular Pathology. Philadelphia, PA: Elsevier Saunders; 2009
• 15 Sharif S, Ferner R, Birch JM , et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol 2006; 24 (16) 2570-2575
• 16 Sung L, Anderson JR, Arndt C, Raney RB, Meyer WH, Pappo AS. Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. J Pediatr 2004; 144 (5) 666-668
• 17 Tucker T, Schnabel C, Hartmann M , et al. Bone health and fracture rate in individuals with neurofibromatosis 1 (NF1). J Med Genet 2009; 46 (4) 259-265
• 18 Heervä E, Koffert A, Jokinen E , et al. A controlled register-based study of 460 neurofibromatosis 1 patients: increased fracture risk in children and adults over 41 years of age. J Bone Miner Res 2012; 27 (11) 2333-2337
• 19 Agaimy A, Vassos N, Croner RS. Gastrointestinal manifestations of neurofibromatosis type 1 (Recklinghausen's disease): clinicopathological spectrum with pathogenetic considerations. Int J Clin Exp Pathol 2012; 5 (9) 852-862
• 20 Evans DG, Huson SM, Donnai D , et al. A clinical study of type 2 neurofibromatosis. Q J Med 1992; 84 (304) 603-618
• 21 Baser ME, Friedman JM, Aeschliman D , et al. Predictors of the risk of mortality in neurofibromatosis 2. Am J Hum Genet 2002; 71 (4) 715-723
• 22 Baser ME, Friedman JM, Wallace AJ, Ramsden RT, Joe H, Evans DG. Evaluation of clinical diagnostic criteria for neurofibromatosis 2. Neurology 2002; 59 (11) 1759-1765
• 23 Trofatter JA, MacCollin MM, Rutter JL , et al. A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell 1993; 72 (5) 791-800
• 24 Rouleau GA, Merel P, Lutchman M , et al. Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature 1993; 363 (6429) 515-521
• 25 Evans DG, Ramsden RT, Shenton A , et al. Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. J Med Genet 2007; 44 (7) 424-428
• 26 Love S, Perry A, Ironside J, Budka H. Greenfield's Neuropathology. 9th ed. Boca Raton, FL: CRC Press; 2015
• 27 Selvanathan SK, Shenton A, Ferner R , et al. Further genotype—phenotype correlations in neurofibromatosis 2. Clin Genet 2010; 77 (2) 163-170
• 28 Smith MJ, Higgs JE, Bowers NL , et al. Cranial meningiomas in 411 neurofibromatosis type 2 (NF2) patients with proven gene mutations: clear positional effect of mutations, but absence of female severity effect on age at onset. J Med Genet 2011; 48 (4) 261-265
• 29 Stivaros SM, Stemmer-Rachamimov AO, Alston R , et al. Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2. J Med Genet 2015; 52 (8) 557-562
• 30 Dewan R, Pemov A, Kim HJ , et al. Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas. Neuro-oncol 2015; 17 (4) 566-573
• 31 Maniakas A, Saliba I. Neurofibromatosis type 2 vestibular schwannoma treatment: a review of the literature, trends, and outcomes. Otol Neurotol 2014; 35 (5) 889-894
• 32 Neff BA, Wiet RM, Lasak JM , et al. Cochlear implantation in the neurofibromatosis type 2 patient: long-term follow-up. Laryngoscope 2007; 117 (6) 1069-1072
• 33 Hamada Y, Iwaki T, Fukui M, Tateishi J. A comparative study of embedded nerve tissue in six NF2-associated schwannomas and 17 nonassociated NF2 schwannomas. Surg Neurol 1997; 48 (4) 395-400
• 34 Plotkin SR, Merker VL, Halpin C , et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol 2012; 33 (6) 1046-1052
• 35 Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol 2014; 73 (6) 1197-1204
• 36 Hilton DA, Hanemann CO. Schwannomas and their pathogenesis. Brain Pathol 2014; 24 (3) 205-220
• 37 Stemmer-Rachamimov AO, Ino Y, Lim ZY , et al. Loss of the NF2 gene and merlin occur by the tumorlet stage of schwannoma development in neurofibromatosis 2. J Neuropathol Exp Neurol 1998; 57 (12) 1164-1167
• 38 Berg JC, Scheithauer BW, Spinner RJ, Allen CM, Koutlas IG. Plexiform schwannoma: a clinicopathologic overview with emphasis on the head and neck region. Hum Pathol 2008; 39 (5) 633-640
• 39 Hébert-Blouin MN, Amrami KK, Scheithauer BW, Spinner RJ. Multinodular/plexiform (multifascicular) schwannomas of major peripheral nerves: an underrecognized part of the spectrum of schwannomas. J Neurosurg 2010; 112 (2) 372-382
• 40 Bendon CL, Furniss D, Giele HP. Comparison of outcomes of peripheral nerve schwannoma excision in neurofibromatosis type 2 patients and non-neurofibromatosis type 2 patients: A case control study. J Plast Reconstr Aesthet Surg 2015; 68 (9) 1199-1203
• 41 Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. Arch Dis Child 1999; 81 (6) 496-499
• 42 Plotkin SR, O'Donnell CC, Curry WT, Bove CM, MacCollin M, Nunes FP. Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. J Neurosurg Spine 2011; 14 (4) 543-547
• 43 McLaughlin ME, Pepin SM, Maccollin M, Choopong P, Lessell S. Ocular pathologic findings of neurofibromatosis type 2. Arch Ophthalmol 2007; 125 (3) 389-394
• 44 Koontz NA, Wiens AL, Agarwal A, Hingtgen CM, Emerson RE, Mosier KM. Schwannomatosis: the overlooked neurofibromatosis?. AJR Am J Roentgenol 2013; 200 (6) W646-53
• 45 MacCollin M, Chiocca EA, Evans DG , et al. Diagnostic criteria for schwannomatosis. Neurology 2005; 64 (11) 1838-1845